Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 30, 2014, 02:34:40 PM

Login with username, password and session length


Members
  • Total Members: 23587
  • Latest: obie1
Stats
  • Total Posts: 640577
  • Total Topics: 48654
  • Online Today: 220
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: HTB supplement: 2011 pipeline report for HIV, HCV and TB  (Read 2081 times)

0 Members and 1 Guest are viewing this topic.

Offline newt

  • Member
  • Posts: 3,885
  • the one and original newt
HTB supplement: 2011 pipeline report for HIV, HCV and TB
« on: July 13, 2011, 12:32:25 PM »
HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, vaccines, and preventive technologies in development

writers from the Treatment Action Group (TAG), New York and HIV i-Base, London with contribution from Jonathan Berger of Section 27, South Africa on patents, IP and treatment access.

http://i-base.info/htb/date/2011/07

Selected highlights from the executive summary:

"As this i-Base and TAG 2011 Pipeline Report makes clear, medically, the prospect for people with HIV, hepatitis C virus (HCV), and tuberculosis (TB) to live long and healthy lives and in the cases of HCV and TB, to be cured rapidly with safe, effective, oral combination therapy have never been better."

"Politically and economically, the world's activists and political leaders face a crisis in which the former must persuade the latter to redirect billions of dollars from unproductive wars into life-saving health research and access programmes, at home and internationally."

"As the writers of this report reveal, the prospects for dramatic indeed in some cases revolutionary changes in prevention and treatment for the three diseases in the next decade are amazingly good. Decades of high-quality research, increased investment, and growing and targeted community-based activism have set the scene for the possibility for the first time since HIV/AIDS emerged in 1981 to make dramatic reductions in new HIV infections worldwide, while saving the lives of as many of the 34 million currently infected who can access therapy. Treatment is continually improving, with modern combinations dramatically less toxic, more tolerable, and easier to take than the first-generation ART combinations of the 1990s."

"Contrary to the predictions of obstinate pessimists who constantly bemoan the imminent emptying of the ARV pipeline [...] the 2011 HIV treatment pipeline is robust indeed, with twelve agents and fixed-dose combinations (FDCs) in phases II or III, still more in phase I, and two new drugs or formulations already approved in the last year the NNRTIs rilpivirine (Edurant) from Tibotec/J&J (although when this will be preferred in treatment-naive patients is unclear), and Boehringer Ingelheim's extended-release formulation of nevirapine, Viramune XR (just in time for the patent expiry on the original). Two new integrase inhibitors elvitegravir and dolutegravir are in late stages of development, both formulated in novel FDCs. This year's pipeline is at least as full as that of any year documented by TAG in our annual ARV pipelines since 2003."

- matt
"The object is to be a well patient, not a good patient"

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.